Teva Pharmaceuticals USA Inc reported on Tuesday the receipt of approval from the Food and Drug Administration (FDA) for an autoinjector device for AJOVY (fremanezumab-vfrm) injection for treating migraine.
AJOVY is the only FDA-approved anti-CGRP that offers the flexibility of quarterly (675 mg) or monthly (225 mg) dosing options and the healthcare providers will be able to decide if an autoinjector is the right administration option for their needs.
In conjunction, the company's AJOVY autoinjector is expected to be available to patients in the coming months.
Teva Pharmaceuticals USA Inc is an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)( TASE:TEVA), which has been developing and producing medicines to improve people's lives for more than a century.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval